|  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Patient** | **Gender** | **Age** | **Diagnosis** | **Disease**  **state** | **Transplant**  **type** | **Conditioning** | **Antifungal**  **drugs** | **aGVHD** | **cGVHD** | **Treatment before ALS** | **ALS** | | | | |
| **Treatment After ALS** | **Type** | **occurrence** | **duration** | **prognosis** | **cause** |
| 1 | F | 5 | AML | CR | Haplo-HSCT | BU/CY | Voriconazole | Ⅱ | Extensive | MP (2mg/kg) + FK + MMF + CD25 + Anti-TNF-α | IPS/ME/SE | +198d | 5d | die | GVHD |
| Sirolimus |
| 2 | M | 12 | AML | CR | MUD-HSCT | BU/CY | Voriconazole | Ⅲ | —— | MP (0.5mg/kg) + FK + MMF | BOS/ME/SE | +66d | 32d | CR | —— |
| FAM + MSC + Imatinib + ruxolitinib +pirfenidone |
| 3 | F | 7 | AML | CR | Haplo-HSCT | BU/CY | posaconazole | Ⅰ | Extensive | MP (0.25~0.5mg/kg) + CSA + MMF | BOS/ME | +600d | 13d | CR | —— |
| FAM + Imatinib + ruxolitinib |
| 4 | F | 4 | ALL | CR | Haplo-HSCT | TBI/CY | Voriconazole | Ⅱ | Extensive | MP (1mg/kg) + FK + MMF + CD25 + Anti-TNF-α | IPS/ME/SE/pneumothorax | +79d | 61d | die | ALS |
| MP (1.5mg/kg) + Imatinib |
| 5 | M | 4 | ALL | CR | Haplo-HSCT | BU/CY | Voriconazole | —— | Localized | MP (0.25~0.5mg/kg) + CSA + MMF | IPS/ME/SE/Scrotal emphysema/pneumothorax | +287d | 84d | cure | —— |
| MSC + closed chest drainage |
| 6 | M | 9 | AML | CR | Haplo-HSCT | TBI/CY | posaconazole | Ⅰ | Extensive | MP (0.25~0.5mg/kg) + CSA | BOS/ME/SE | +253d | 57d | cure | —— |
| MP (1.5mg/kg) + CSA + MMF |
| 7 | M | 1 | AML | NR | Haplo-HSCT | BU/CY | posaconazole | Ⅰ | —— | None | IPS/ME/SE | +89d | 28d | die | GVHD |
| MP (1mg/kg) + percutaneous gas drainage |
| 8 | F | 6 | ALL | NR | Haplo-HSCT | BU/CY | posaconazole | Ⅰ | —— | CSA | BOS/ME/SE | +213d | 230d | CR | —— |
| MP (2mg/kg) + Sirolimus + MMF + FAM + Imatinib + ruxolitinib + Pirfenidone + CD25 + Anti-TNF-α+ Rituximab + Infliximab + percutaneous gas drainage |
| 9 | M | 3 | AML | CR | Haplo-HSCT | BU/CY | posaconazole | Ⅲ | —— | MP (0.25~0.5mg/kg) + FK + MMF | BOS/ME/SE | +125d | 125d | CR | —— |
| MP (2mg/kg) + FK + MMF + FAM + Infliximab + Imatinib + ruxolitinib + Pirfenidone |
| 10 | F | 2 | AML | NR | Haplo-HSCT | BU/CY | posaconazole | Ⅱ | Extensive | CSA+MMF | IPS/ME | +207d | 4d | die | ALS |
| MP (2mg/kg) + CAS + MMF + Anti-TNF-α + Infliximab |
| 11 | F | 14 | ALL | NR | Haplo-HSCT | BU/CY | Voriconazole | Ⅱ | —— | MP (0.25~0.5mg/kg) + CSA + MMF | IPS/ME | +87d | 61d | cure | —— |
| MP (1mg/kg) + FK + MMF |
| 12 | M | 5 | ALL | CR | Haplo-HSCT | BU/CY | Voriconazole | Ⅲ | —— | MP (0.5mg/kg) + CSA + MMF | IPS/ME/Scrotal emphysema/pneumopericardium/pneumoperitoneum | +407d | 33d | CR | —— |
| MP (2mg/kg) + CAS + FK + MMF + MSC + FAM |
|  |  |  |  |  |  |  |  |  | Extensive | MP (0.25mg/kg) + FK + MMF | IPS/pneumothorax | +1366d | 5d | CR | —— |
| MSC + FAM |
| 13 | M | 10 | ALL | CR | MUD-HSCT | TBI/CY | Voriconazole | —— | Extensive | MP (0.25~0.5mg/kg) + CSA | BOS/pneumothorax | +1202d | 60d | CR | —— |
| MP (1mg/kg) + FK + MMF + FAM + MSC |
|  |  |  |  |  |  |  |  |  | —— | MP (0.25mg/kg) + FK + MMF | BOS/pneumothorax | +1490d | 102d | die | GVHD |
| Imatinib + closed chest drainage |
| 14 | F | 6 | AML | CR | Haplo-HSCT | BU/CY | posaconazole | Ⅲ | Localized | MP (0.5mg/kg) + CSA + MMF | BOS/ME/SE/pneumoperitoneum / pneumatosis intestinalis | +314d | 362d | CR | —— |
| FAM + Imatinib + ruxolitinib + Pirfenidone |
| 15 | M | 1 | AML | CR | MUD-HSCT | BU/CY | posaconazole | Ⅱ | Localized | MP (0.5mg/kg) + CSA + MMF | IPS/ME | +365d | 29d | CR | —— |
| MP (1mg/kg) + FK + MMF + FAM + Imatinib + ruxolitinib |
| 16 | F | 14 | AML | PR | Haplo-HSCT | BU/CY | Voriconazole | —— | Localized | MP (0.5mg/kg) + CSA + MMF | BOS/ME/SE | +385d | 70d | CR | —— |
| MP (2mg/kg) + FK + MMF + ruxolitinib |
| 17 | M | 14 | AML | PR | Haplo-HSCT | TBI/CY | posaconazole | Ⅲ | Extensive | MP (1mg/kg) + FK + MMF + FAM + CD25 + Anti-TNF-α + ALG | BOS/ME/SE | +665d | 53d | cure | —— |
| MP (2mg/kg) + ruxolitinib |
| 18 | M | 16 | AML | CR | Haplo-HSCT | BU/CY | posaconazole | Ⅰ | Extensive | MP (0.25~0.5mg/kg) + FK + MMF | BOS/ME/SE/intraspinal air | +129d | 17d | cure | —— |
| MP (1mg/kg) + Sirolimus + CD25 + Anti-TNF-α + MSC |
|  |  |  |  |  |  |  |  |  | Extensive | MP (0.25mg/kg) | BOS/ME/SE/pneumothorax | +530d | 199d | die | GVHD |
| Maintenance |
| 19 | F | 13 | AA | CR | Haplo-HSCT | BU/CY | posaconazole | Ⅲ | Localized | MP (1.5mg/kg) + FK + MMF + CD25 + Anti-TNF-α | BOS/ME | +47d | 18d | cure | —— |
| FAM |
| 20 | F | 13 | ALL | CR | Haplo-HSCT | BU/CY | Voriconazole | Ⅱ | Localized | CSA | IPS/ME /pneumothorax | +408d | 185d | cure | —— |
| MP (2mg/kg) + FK + MMF + FAM |
| 21 | M | 5 | ALL | CR | Haplo-HSCT | TBI/CY | Voriconazole | Ⅳ | —— | MP (3mg/kg) + FK + MMF + CD25 + Anti-TNF-α | IPS/ME | +50d | 5d | die | GVHD |
| Maintenance |
| 22 | M | 15 | AA | CR | Haplo-HSCT | BU/CY | Voriconazole | Ⅲ | Extensive | MP (2mg/kg) + FK + MMF + CD25 + Anti-TNF-α | IPS/ME | +29d | 29d | cure | —— |
| Maintenance |
|  |  |  |  |  |  |  |  |  | —— | MP (0.25mg/kg) | IPS/ME | +162d | 13d | die | GVHD |
| Maintenance |
| 23 | M | 15 | AA | CR | Haplo-HSCT | BU/CY | Voriconazole | Ⅰ | Extensive | MP (0.25mg/kg) + FK + MMF + Anti-TNF-α + MSC | IPS/ME/SE | +270d | 31d | cure | —— |
| MP (0.5mg/kg) + CD25 + FAM |
| 24 | F | 12 | AML | CR | Haplo-HSCT | BU/CY | posaconazole | Ⅲ | Extensive | MP (2mg/kg) + FK + MMF + CD25 + Anti-TNF-α+ ALG + MSC | BOS/ME/SE/pneumothorax | +101d | 141d | die | GVHD |
| ruxolitinib |
| 25 | M | 13 | AML | NR | Haplo-HSCT | TBI/CY | posaconazole | Ⅱ | Localized | MP (0.5mg/kg) + CSA | BOS/ME/SE/pneumothorax | +340d | 186d | CR | —— |
| MMF + MSC + ruxolitinib |
| 26 | M | 4 | AML | CR | Haplo-HSCT | BU/CY | posaconazole | Ⅱ | Localized | MP (0.5mg/kg) + CSA + MMF | BOS/ME/SE | +424d | 110d | CR | —— |
| MP (1mg/kg) + FAM + ruxolitinib + Pirfenidone |
| 27 | M | 11 | ALL | CR | Haplo-HSCT | TBI/CY | posaconazole | Ⅰ | Extensive | MP (0.25mg/kg) + CSA + MMF | BOS/ME | +330d | 4d | CR | —— |
| MP (0.5mg/kg) + FAM + Imatinib + ruxolitinib |
| 28 | F | 12 | AML | CR | Haplo-HSCT | BU/CY | posaconazole | Ⅱ | Extensive | MP (0.25mg/kg) + CSA + MMF | IPS/ME/SE | +524d | 131d | die | GVHD |
| MP (1mg/kg) + FK + FAM + MSC + ruxolitinib |